Literature DB >> 16118813

Modelling the association between adherence and viral load in HIV-infected patients.

Bernard Vrijens1, Els Goetghebeur, Erik de Klerk, Richard Rode, Steve Mayer, John Urquhart.   

Abstract

The primary objective of this paper is to investigate the effect of adherence to prescribed antiretroviral therapy on virologic response measured repeatedly over time in HIV-infected patients. To this end observations on plasma viral load (HIV RNA) assessed in copies/ml are categorized into four clinically meaningful states, [0--50[, [50--400[, [400--2000[, [2000 and up. A time-dependent continuation ratio model is used to analyse longitudinal ordinal responses. The main challenge lies in modelling dependencies over time and using information contained in the data efficiently to establish a dynamic relation between observed patient adherence and viral load. Among the several measures of adherence investigated, two specifically account for long periods of time without intake. One is derived from the third moment of the inter-dose interval distribution, while the second reflects internal drug exposure using pharmacokinetic parameters. The approach is applied to a clinical trial involving 35 patients who were followed over 12 months. Results demonstrate a significant relation between patient adherence and virologic response. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118813     DOI: 10.1002/sim.2130

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  25 in total

1.  A probabilistic approach for the evaluation of pharmacological effect induced by patient irregular drug intake.

Authors:  Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-06-25       Impact factor: 2.745

2.  A technical note concerning non-adherence to drug therapy: exact expressions for the mean and variance of drug concentration.

Authors:  Steve Gallivan; Christina Pagel; Martin Utley; Bryony Dean Franklin; Katja Taxis; Nick Barber
Journal:  Health Care Manag Sci       Date:  2008-09

3.  Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens.

Authors:  Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

Review 4.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

5.  How to report adherence to treatment as clinically relevant data-making a case of CML and TKI.

Authors:  Lucas Miyake Okumura
Journal:  Support Care Cancer       Date:  2017-07-11       Impact factor: 3.603

6.  A DYNAMIC BAYESIAN NONLINEAR MIXED-EFFECTS MODEL OF HIV RESPONSE INCORPORATING MEDICATION ADHERENCE, DRUG RESISTANCE AND COVARIATES().

Authors:  Yangxin Huang; Hulin Wu; Jeanne Holden-Wiltse; Edward P Acosta
Journal:  Ann Appl Stat       Date:  2011       Impact factor: 2.083

7.  Compliance spectrum as a drug fingerprint of drug intake and drug disposition.

Authors:  Olivier Barrière; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-12-19       Impact factor: 2.745

8.  Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.

Authors:  Jean-Jacques Parienti; Aurélie Barrail-Tran; Xavier Duval; Georges Nembot; Diane Descamps; Marie Vigan; Bernard Vrijens; Xavière Panhard; Anne-Marie Taburet; France Mentré; Cécile Goujard
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

9.  Effects of daily adherence to antihypertensive medication on blood pressure control.

Authors:  Adam J Rose; Mark E Glickman; Meredith M D'Amore; Michelle B Orner; Dan Berlowitz; Nancy R Kressin
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-02-16       Impact factor: 3.738

10.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.